Développement de méthodes d'imagerie pour étudier le métabolisme cérébral en oxygène du nouveau-né à risque

 

Mathieu Dehaes

Centre hospitalier universitaire Sainte Justine

 

Domaine : santé de la mère, des enfants et des adolescents

Programme Chercheurs-boursiers - Junior 2

Concours 2019-2020

The neonatal brain is particularly vulnerable to biological consequences of three major conditions: prematurity, birth asphyxia and congenital heart disease. Foetal and neonatal brain lesions observed in such conditions are associated with adverse neurodevelopment. Although neonatal mortality rates associated with such conditions have decreased due to advances in clinical care, there is a high prevalence of significant neurodevelopmental deficits. Therefore, there is an urgent need to have reliable imaging tools and procedures to detect lesions in neonates.

My previous research activities were focused on the development of safe bedside neonatal brain imaging techniques. In particular, my Junior 1 was instrumental in obtaining operating funds, recruiting highly qualified personnel and developing a productive laboratory. In the next four years, my research program will focus on developing new and improving current methods of neonatal brain imaging, and assessing their ability to identify early brain alterations and predict neurodevelopment in neonates at-risk.

In particular, my research program will focus on the identification of early brain alterations in at-risk neonates with a combination of emerging techniques based on advanced near infrared spectroscopy and electroencephalography. Respectively, these techniques allow the measurement of an index of cerebral O2 metabolism and electrical background brain activity. Current and future studies described in my program aim to validate these measures as early predictors of neonatal compromise that may lead to developmental delay.

The successful completion of these projects will provide the necessary data on this emerging technology to submit a clinical trial application to Health Canada. Ultimately the goal of my research is to license this advanced technology and make it accessible for clinical use on Canadian children.